A recent in vitro study suggested that it might be worth re-assessing these results according to the PTEN, GSK3b phosphorylation and FBW7 status, since genotoxic therapies induce ERG degradation in prostate cancer cells only when these three proteins are functional [50]. This evidence concerns the gene ERG and prostate carcinoma.